Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug ...

Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Verastem Inc (VSTM) stock saw a modest uptick, ending the day at $5.17 which represents a slight increase of $1.50 or 40.87% from the prior close of $3.67. The stock opened at $4.91 and touched a low ...

Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...

Verastem (NASDAQ:VSTM) said the FDA has accepted its New Drug Application for accelerated approval of its drugs avutometinib ...

Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025 ...

Verastem Oncology (Nasdaq: VSTM) said yesterday that the FDA has accepted its new drug application (NDA) for avutometinib, in combination with defactinib, which aim to treat adult patients with ...

Highlights,FDA grants Priority Review for new treatment combination in recurrent KRAS mutant LGSOC.,Phase 2 trial results ...